Supplemental digital content is available in the text.
From the *Department of Medicine, School of Medicine & Public Health, and †Departments of Biostatistics and Medical Informatics & Population Health Sciences, University of Wisconsin, Madison, WI; and ‡Centegra Health System, Crystal Lake, IL.
Sources of support: Atlantic Philanthropies; the John A. Hartford Foundation; the Association for Specialty Professors; the American College of Rheumatology; and the National Institute of Health (K23-ARO50995, NIAMS). K.E.H. receives current salary support from the National Institute of Health [RO1 AG028739]. C.M.B. receives support from NIH-NIAMS (K23 AR062381-01). These agencies had no role in the design, conduct, or analysis of the study or writing of the article.
The manuscript is not under review elsewhere. No similar or related manuscripts related to this study exist.
K.E.H. is a consultant to Takeda Pharmaceuticals and Deltanoid Pharmaceuticals. All other authors declare no conflict of interest.
Correspondence: Karen E. Hansen, MD, MS, University of Wisconsin School of Medicine and Public Health, Room 4124, MFCB, 1685 Highland Ave, Madison, WI. E-mail: firstname.lastname@example.org.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.jclinrheum.com).